ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2702

Immunophenotyping of Rheumatoid Arthritis Reveals the Linkage Between HLA-DRB1 Genotype, CXCR4 Expressions on Memory CD4+ T Cells, and Disease Activity

Yasuo Nagafuchi1, Hirofumi Shoda1, Shuji Sumitomo1, Shinichiro Nakachi1, Rika Kato2, Yumi Tsuchida2, Haruka Tsuchiya2, Keiichi Sakurai2, Norio Hanata2, Shoko Tateishi2, Hiroko Kanda2, Keishi Fujio1 and Kazuhiko Yamamoto1, 1Department of Allergy and Rheumatology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan, 2Graduate School of Medicine, The University of Tokyo, Tokyo, Japan

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: Chemokine Receptors, genetics, immunology and rheumatoid arthritis (RA)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 10, 2015

Title: Rheumatoid Arthritis - Human Etiology and Pathogenesis Poster III

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: The HLA-DRB1 is the strongest genetic risk factor for rheumatoid arthritis (RA). Although this fact suggests a pivotal role for adaptive immunity in RA, the linkage between HLA-DRB1 genotype and lymphocytes activation remains unclear.

Methods: We analyzed 91 HLA-DRB1 genotyped RA patients and 110 healthy donors by 24-subset immunophenotyping of peripheral blood mononuclear cells (PBMC) combined with CXCR4 expression analysis, HLA-DR quantification, and multiplex serum cytokine analysis. The correlation between these biomarkers and clinical parameters, such as the titer of anti-citrullinated peptide antibody (ACPA) and DAS28esr, was examined. 20 RA patients were analyzed at the initiation of CTLA4-Ig treatment and after 6-months of treatment. PBMC of healthy donors were cultured for 5 days with IL-21 and anti-HLA-DR antibody to assess CXCR4 expression on CD4+ T cells.

Results: The frequency of CXCR4-expressing memory CD4+ T cells, not that of classical Th1 or Th17 cells, was significantly associated with DAS28esr and the titer of ACPA. RA patients with susceptible haplotype of HLA-DR (shared epitope: SE) displayed significantly higher frequency of memory CD4+ T cells and higher positivity for CXCR4 on memory CD4+ T cells than healthy donors and RA patients without SE. Moreover, the frequency of CXCR4-expressing memory CD4+ T cells displayed a significant correlation to the expression level of HLA-DR on B cells, which was elevated in RA patients with SE. In vitro experiments indicated that the increased CXCR4 expression on RA memory CD4+ T cells was dependent both on IL-21 and HLA-DR expression on antigen presenting cells. In clinic, higher frequency of CXCR4-expressing memory CD4+ T cells predicted better therapeutic effects of CTLA4-Ig.

Conclusion: These findings demonstrate a potential contribution of HLA-DR on B cells to the development of memory CD4+ T cells which is associated with disease activity. Identification of CXCR4 on memory T cells as a biomarker may promote the understanding of the linkage between genetic risk factor and adaptive immunity in RA.


Disclosure: Y. Nagafuchi, None; H. Shoda, None; S. Sumitomo, None; S. Nakachi, None; R. Kato, None; Y. Tsuchida, None; H. Tsuchiya, None; K. Sakurai, None; N. Hanata, None; S. Tateishi, None; H. Kanda, None; K. Fujio, Astellas, BMS, Daiichi-Sankyo, MitsubishiTanabe, Pfizer, Santen, Takeda, Chugai, Eisai, Taisho Toyama, UCB, and Janssen., 2; K. Yamamoto, UCB Pharma, Pfizer, Abbott, Santen, Mitsubish-Tanabe, Eisai, 2,UCB Pharma, Pfizer, Abbott, Bristol-Myers Squibb, Roche, Chugai, Mitsubish-Tanabe, Eisai, 5.

To cite this abstract in AMA style:

Nagafuchi Y, Shoda H, Sumitomo S, Nakachi S, Kato R, Tsuchida Y, Tsuchiya H, Sakurai K, Hanata N, Tateishi S, Kanda H, Fujio K, Yamamoto K. Immunophenotyping of Rheumatoid Arthritis Reveals the Linkage Between HLA-DRB1 Genotype, CXCR4 Expressions on Memory CD4+ T Cells, and Disease Activity [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/immunophenotyping-of-rheumatoid-arthritis-reveals-the-linkage-between-hla-drb1-genotype-cxcr4-expressions-on-memory-cd4-t-cells-and-disease-activity/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/immunophenotyping-of-rheumatoid-arthritis-reveals-the-linkage-between-hla-drb1-genotype-cxcr4-expressions-on-memory-cd4-t-cells-and-disease-activity/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology